GlassScriptPhysician profile
Linda T Arakaki
NPI 1699823815
$6,016.79
in general payments reported to CMS, 2019-2025
21 companies · $910 in 2025
The $910 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $884 · 2020: $223 · 2021: $1,004 · 2022: $820 · 2023: $1,120 · 2024: $1,055 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,030 · Entertainment: $54.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,030.28 |
| Entertainment | $54.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,420.80 | 2019-2025 | Total30, Precision7 |
| Bausch & Lomb Americas INC. | $1,202.24 | 2022-2025 | Infuse, Biotrue One Day, Infuse Multifocal |
| Coopervision INC. | $731.05 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $600.24 | 2019-2021 | |
| Optos, INC. | $446.42 | 2019-2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Lkc Technologies, INC. | $246.01 | 2023-2024 | |
| Abbvie INC. | $227.65 | 2022-2023 | Vuity |
| Shire North American Group INC | $142.41 | 2019 | |
| Lombart Brothers, INC. | $141.19 | 2025 | Opd-III |
| Tarsus Pharmaceuticals, INC. | $133.54 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $124.99 | 2019 | |
| Dompe US, INC. | $118.06 | 2024 | Oxervate |
| Sight Sciences, INC. | $116.89 | 2025 | Omni Surgical System |
| Allergan, INC. | $98.37 | 2020-2021 | |
| Johnson & Johnson Vision Care, INC. | $65.29 | 2022-2023 | Acuvue |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $59.69 | 2025 | Photrexa Viscous and Photrexa |
| Amgen INC. | $46.17 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $39.33 | 2023 | Tepezza |
| Oyster Point Pharma, INC. | $22.38 | 2023 | Tyrvaya |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Kala Pharmaceuticals, INC. | $16.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Arakaki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.